SignalFDA/Bio

RARE Stock Up 13% on FDA Approval of Sanfilippo Syndrome Gene Therapy

FDA approval of Sanfilippo gene therapy drives RARE stock up 13%.

What changed

FDA approval of Sanfilippo gene therapy drives RARE stock up 13%.

Why it matters

FDA approval of Sanfilippo gene therapy drives RARE stock up 13%. — impact context not separately stored; see What changed.

Sources